Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Aprea Therapeutics
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Confirmed High Grade Serous Ovarian Cancer, and positive nuclear immunohistochemical (IHC) staining for p53
Disease Progression between 4 weeks - 6 months after the last platinum-based treatment was administered
At least a single measurable lesion
Adequate organ function prior to registration
Toxicities from previous cancer therapies (excluding alopecia) must have recovered to grade 1 (defined by National Cancer Institute \[NCI\] Common Terminology Criteria for Adverse Events \[CTCAE\] version 4.0). Chronic stable grade 2 peripheral neuropathy secondary to neurotoxicity from prior therapies may be considered on a case by case basis
ECOG performance status of 0 to 2
You may not be if
Prior exposure to cumulative doses of doxorubicin \>400 mg/m2 or epirubicin \>720 mg/m2
Hypersensitivity to PLD or to any of the excipients
Unable to undergo imaging by either CT scan or MRI
Evidence of any other medical conditions (such as psychiatric illness, infectious diseases, neurological conditions, physical examination or laboratory findings) that may interfere with the planned treatment, affect patient compliance or place the patient at high risk from treatment related complications
Concurrent malignancy requiring therapy (excluding non-invasive carcinoma or carcinoma in situ)
Is taking concurrent (or within 4 weeks prior to registration) chemotherapy, immunotherapy, radiotherapy, or any ancillary therapy that is considered to be investigational (i.e., used for non-approved indications(s) and in the context of a research investigation). Supportive care measures are allowed. Palliative limited radiation therapy for pain reduction is allowed
Clareo Health | p53 Activation in Platinum-Resistant High Grade Serous Ovarian Cancer, a Study of PLD With APR-246
